SAHPRA Biosimilars Approval: Pathway Analysis and Market Implications

Key Takeaways

• Step-wise comparability: SAHPRA requires a tailored comparability process beginning with quality studies to determine the extent of non-clinical and clinical data needed, as outlined in SAHPRA's August 2014 guidance.
• Comprehensive data requirements: Applications must include pharmaceutical quality data, in vitro biostudies, pharmacokinetic and pharmacodynamic studies, and confirmatory clinical trials where necessary.
• Monoclonal antibody specifics: SAHPRA provides product-specific guidance for monoclonal antibody biosimilars in Annexure 1 of its guidance document.
• International alignment: SAHPRA's framework aligns with WHO guidelines, FDA guidance, and EMA regulations for biosimilar evaluation.
• Risk management requirements: Biosimilar applications must include a risk management plan and pharmacovigilance strategy for post-market monitoring.

What Is SAHPRA's Biosimilar Regulatory Framework?

SAHPRA serves as South Africa's primary regulatory authority for health products, including biologics and biosimilars. Unlike generic pharmaceutical medicines, which are identical to their reference products, biological medicines exhibit natural variability inherent to living systems. This fundamental difference requires a distinct regulatory approach.

The SAHPRA Biosimilar Medicines Guidance, finalized in August 2014, establishes the current framework. This document outlines specific information required for registration of biosimilar medicines containing well-characterized recombinant DNA-derived therapeutic proteins. The guidance applies to biological medicines similar to reference products already registered in South Africa.

Vaccines remain excluded from SAHPRA's biosimilar guidance scope, even when manufactured using recombinant DNA technology. The framework also addresses monoclonal antibodies through product-specific requirements detailed in Annexure 1.

What Data Requirements Does SAHPRA Mandate?

SAHPRA's biosimilar approval pathway rests on comprehensive comparability studies demonstrating that a biological medicine is highly similar to its reference product. The process follows a step-wise approach tailored to each product's characteristics.

Quality and Non-Clinical Data

The foundation of any biosimilar application comprises pharmaceutical quality data. Manufacturers must demonstrate physicochemical and functional similarity through analytical studies comparing the biosimilar to the reference product. This includes structural characterization, purity assessment, and potency testing.

In vitro biostudies evaluate biological activity and binding properties. Non-clinical animal studies may be required depending on the complexity of the molecule and the extent of analytical similarity established. SAHPRA reserves the right to waive certain requirements based on the nature of the comparability exercise, provided applicants offer scientific and technical justification.

Clinical Data Requirements

Clinical development for SAHPRA approval follows a tiered approach. Pharmacokinetic (PK) studies establish similarity in absorption, distribution, metabolism, and elimination. Pharmacodynamic (PD) studies demonstrate comparable biological effects when feasible.

Confirmatory PK/PD studies or efficacy trials become necessary when analytical and non-clinical data leave residual uncertainty. The scope depends on the complexity of the biosimilar and the therapeutic area. All clinical studies must use South African-registered reference products as comparators.

Immunogenicity and Risk Management

Immunogenicity assessment forms a critical component of SAHPRA's requirements. Biosimilar applications must include comprehensive evaluation of immune response potential, including antibody detection and characterization. The clinical significance of observed immunogenicity requires careful assessment.

SAHPRA mandates a risk management plan addressing pharmacovigilance requirements for post-market monitoring. This ensures ongoing surveillance of safety signals once the biosimilar enters clinical use.

How Does SAHPRA Compare to Global Regulators?

SAHPRA's approach reflects international convergence in biosimilar regulation while incorporating South African context. The framework aligns with the WHO Guidelines on Evaluation of Biosimilars, which provide globally acceptable principles for national regulatory authorities.

Comparison of Biosimilar Regulatory Approaches

Regulator	Key Guidance	Approach
SAHPRA	August 2014 Guidance	Step-wise comparability; South Africa-specific requirements
FDA	BPCI Act; Biosimilars Action Plan	Comparability plus interchangeability pathway
EMA	2006 Biosimilar Framework	Pioneer step-wise comparability; extensive guidance library
WHO	2013 Guidelines	Global reference standard for national adoption

The FDA's biosimilar program, established under the Biologics Price Competition and Innovation Act of 2009, includes an interchangeability designation beyond basic biosimilarity. SAHPRA's guidance addresses interchangeability considerations but focuses primarily on establishing biosimilarity through the step-wise comparability process.

EMA pioneered biosimilar regulation globally, with its first guidance issued in 2006. The EMA biosimilar framework now encompasses extensive product-specific guidelines and a tailored scientific advice pilot program launched in 2017. SAHPRA's guidance draws from EMA principles while maintaining independent evaluation authority.

What Are the Market Access Implications?

SAHPRA's structured pathway creates access for biosimilar entry into the South African market. By establishing clear requirements, the framework enables manufacturers to prepare applications with predictable evidentiary standards.

The comparability exercise requirements, while demanding, avoid unnecessary duplication of the full clinical development program conducted for originator biologics. This creates potential for reduced development costs compared to novel biologics, supporting the goal of expanding patient access to affordable treatments.

South Africa's position as a regulatory leader in the Middle East and Africa (MEA) region creates strategic implications beyond its borders. Other African regulatory authorities may reference SAHPRA decisions or adopt similar frameworks, potentially streamlining market access across the continent.

However, the requirement for comprehensive comparability data, including clinical studies when needed, means biosimilar development remains resource-intensive. Manufacturers must balance the investment required against market potential and pricing dynamics in the South African healthcare system.

What Should Manufacturers Consider When Planning SAHPRA Submissions?

Biosimilar manufacturers targeting South Africa must engage early with SAHPRA's requirements. The guidance explicitly states that applicants should adhere to all administrative requirements to avoid delays in processing and evaluation.

Key strategic considerations include:

• Reference product selection: The reference product must be registered in South Africa, not merely in other jurisdictions.
• Quality foundation: Strong analytical similarity data reduces the scope of clinical studies required.
• Scientific advice: SAHPRA allows for consultation on development programs, though formal pathways are less structured than EMA's tailored scientific advice pilot.
• Bridging studies: When foreign clinical data exists, manufacturers may need South African bridging studies to address population-specific factors.

SAHPRA explicitly reserves the right to request additional information beyond the standard guidance requirements. This flexibility allows the authority to address novel scientific questions while creating uncertainty for applicants.

Frequently Asked Questions

Primary Sources

1. SAHPRA. Biosimilar Medicines Quality, Non-clinical and Clinical Requirements. Version 4, August 2014. South African Health Products Regulatory Authority guidance document outlining biosimilar registration requirements.
2. World Health Organization. Guidelines on Evaluation of Biosimilars. WHO Technical Report Series. Global framework for national regulatory authorities licensing biosimilar products.
3. U.S. Food and Drug Administration. Biosimilars: Industry Information and Guidance. FDA guidance on demonstrating biosimilarity and interchangeability under the BPCI Act.
4. European Medicines Agency. Biosimilar Medicines: Marketing Authorisation. EMA regulatory framework for biosimilar approval in the European Union.
5. SAHPRA. Biosimilar Medicine Quality, Non-clinical and Clinical Requirements (Updated). Document SAHPGL-PEM-BIO-02, Version 2, updated December 2025.